The only thing they've realised is FDA rejection & zero commercialisation whilst spending $2m per quarter.
If the revenue doesn't exceed $100k like old mate claims it will. If it's 20k, for instance, or less why would he hang around? The product wouldn't be selling to his expectations and imo the share price will flounder...especially with a CR around the corner.
COVID-19 Instant Screening test, page-416
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 606 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)